Acadia Expands its License Agreement with Neuren to Acquire Ex-North American Rights to Trofinetide and Global Rights to NNZ-2591
Shots:
- Neuren will receive $100M up front & an additional downstream milestone along with royalty for trofinetide & NNZ-2591 & is also eligible to receive an additional fee outside of North America for trofinetide upon achievement of specified revenue milestones (~$170M in EU; ~$110M in Japan; $83M in rest of world)
- Acadia gets an exclusive global right to NNZ-2591, a synthetic analogue of cyclo-glycyl-proline (cGP) in Rett syndrome & Fragile X syndrome. NNZ-2591 is under development in 4 other rare neurodevelopmental syndromes
- Acadia plans to submit a new drug submission for trofinetide in Canada in the next 18mos. with planning for the EU, Asia & other regions. Trofinetide was launched in the US under the brand name Daybue as the first drug approved for Rett syndrome
Ref: Businesswire | Image: Acadia
Related News:- Acadia Pharmaceuticals Launches Daybue (trofinetide) for the Treatment of Rett Syndrome in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
